Organisation paid for research Program year 2025 Source: CMS Open Payments

Wrmccr LLC

Neither a doctor nor a teaching hospital

Research payments

$523,796

56 payments

Through program year 2025, Wrmccr LLC is reported as receiving $523,796 in research payments, across 56 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$24,105	6
2024	Research	$25,336	6
2023	Research	$296,115	29
2022	Research	$171,415	14
2020	Research	$6,825	1

Breakdown

Who paid Research payments · program years 2020–2025

Pfizer Inc. $522,810 54 payments
AbbVie, Inc. $986 2 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $410,724 46 payments
A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $88,967 4 payments
A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $23,119 4 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension $600 1 payment
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension $386 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.